Antigens onto bare skin: a 'painless' paradigm shift in vaccine delivery.
The skin is an attractive route for delivery of vaccines because it is accessible and contains immunocompetent cells. This opens up the possibility that, in the future, vaccines could be administered in a simple, safe and practical way without requiring the use of needles and syringes. This review focuses on the methods developed to deliver vaccines via the intact skin. Candidate vaccine antigens can be delivered topically using particulate delivery systems and patch formulations containing the antigen with an ADP-ribosylating exotoxin as an adjuvant. The duration and type of elicited immune responses depend on the antigen, the adjuvant and the method of delivery. Already, the first clinical trial of transcutaneous delivery of vaccines has demonstrated the proof of the principle. However, despite these successes, there are several challenges ahead to be addressed before vaccines administered with a patch will be available over the counter.
Partidos
Charalambos D
CD
UPR 9021, CNRS, Immunologie et Chimie Thérapeutiques, Institut de Biologie Moléculaire et Cellulaire, 15 rue René Descartes, F-67084, Strasbourg, France. H.Partidos@ibmc.u-strasbg.fr
D000279:Administration, Cutaneous; D000818:Animals; D000941:Antigens / Q000008:administration & dosage / Q000276:immunology; D018073:Haemophilus Vaccines / Q000008:administration & dosage; D006801:Humans; D011135:Polysaccharides, Bacterial / Q000008:administration & dosage; D012867:Skin / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014612:Vaccines / Q000008:administration & dosage*; D018074:Vaccines, Conjugate / Q000008:administration & dosage
D000941:Antigens; D018073:Haemophilus Vaccines; D011135:Polysaccharides, Bacterial; D014612:Vaccines; D018074:Vaccines, Conjugate